Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. Viewhere

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Form 8 (OPD) (Midatech Pharma plc)

4 May 2020 07:00

RNS Number : 7369L
Midatech Pharma PLC
04 May 2020
 

FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Midatech Pharma plc ("Midatech")

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

N/A

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Midatech Pharma plc

(d) Is the discloser the offeror or the offeree?

OFFEROR / OFFEREE

(e) Date position held:

The latest practicable date prior to the disclosure

1 May 2020

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A

If YES, specify which:

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

n/a

n/a

(2) Cash-settled derivatives:

 

n/a

n/a

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

n/a

n/a

 

TOTAL:

n/a

n/a

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

n/a

Details, including nature of the rights concerned and relevant percentages:

n/a

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe (including directors' and other employee options) of any person acting in concert with the party to the offer making the disclosure:

 

Interest of Midatech Directors and connected advisers in Midatech shares:

Name

Number of Shares

% of issued share capital

Rolf Stahel

53,853

0.23

Stephen Stamp

50,000

0.21

Sijmen De Vries

26,242

0.11

Simon Turton

55,325

0.24

 

Interest of Midatech Directors in warrants over Midatech shares:

Name

Number of Warrants

Exercise price

Expiry date

Rolf Stahel

23,856

£10.00

26/02/2022

Sijmen De Vries

21,345

£10.00

26/02/2022

Simon Turton

41,855

£10.00

26/02/2022

 

Interest of Midatech Directors in options over Midatech shares:

Name

No. of options

Exercise price

Vesting date

Expiry date

Stephen Stamp

50,000

£1.05

20,000 if >$20m raised before 08/09/20, 7,500 on 09/09/20, 1,875 each of 12 quarters ending 09/12/23

02/10/2029

Sijmen de Vries

200

£83.80

Vested

20/04/2022

Sijmen de Vries

500

£1.50

Based on share price:

50% at £106.20; 25% at £274.40; 25% at £377.20

30/06/2024

 

 

 

 

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

YES/NO

Supplemental Form 8 (SBL)

YES/NO

 

 

Date of disclosure:

4 May 2020

Contact name:

Stephen Stamp

CEO/CFO

Telephone number:

+44 (0)1235 888300

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
FEESSFFEDESSEFI
Date   Source Headline
14th Aug 20202:05 pmRNSSecond Price Monitoring Extn
14th Aug 20202:00 pmRNSPrice Monitoring Extension
14th Aug 20207:00 amRNSRegistration Statement Declared Effective
10th Aug 20205:36 pmRNSHolding(s) in Company
7th Aug 20207:00 amRNSHolding(s) in Company
6th Aug 20204:54 pmRNSHolding(s) in Company
6th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20207:00 amRNSHolding(s) in Company
5th Aug 20207:00 amRNSHolding(s) in Company
3rd Aug 20203:00 pmRNSHolding(s) in Company
31st Jul 20202:48 pmRNSResult of AGM
30th Jul 202011:00 amRNSPrice Monitoring Extension
30th Jul 20207:00 amRNSHolding(s) in Company
29th Jul 20204:35 pmRNSHolding(s) in Company
27th Jul 20209:40 amRNSBroker Option Fully Exercised
27th Jul 20207:00 amRNSUK Placing to Raise £5.0 million
24th Jul 20201:31 pmRNSHolding(s) in Company
24th Jul 20208:43 amRNSForm 8.3 - Midatech Pharma PLC
23rd Jul 20202:41 pmRNSForm 8.3 - Midatech Pharma plc
23rd Jul 20207:00 amRNSCorporate Update & Formal Sale Process Termination
22nd Jul 20203:25 pmRNSForm 8.3 - Midatech Pharma plc
21st Jul 20202:05 pmRNSSecond Price Monitoring Extn
21st Jul 20202:00 pmRNSPrice Monitoring Extension
21st Jul 202011:05 amRNSSecond Price Monitoring Extn
21st Jul 202011:00 amRNSPrice Monitoring Extension
21st Jul 20209:00 amRNSCollaboration for the Q-Sphera platform
3rd Jul 20205:48 pmRNSPosting of Annual Report & Notice of AGM
3rd Jul 20207:00 amBUSForm 8.3 - Midatech Pharma PLC
30th Jun 20201:37 pmRNSPublication of Annual Report
25th Jun 20203:10 pmRNSHolding(s) in Company
25th Jun 202012:01 pmRNSForm 8.3 - Midatech Pharma PLC
24th Jun 20205:18 pmBUSForm 8.3 - Midatech Pharma plc
24th Jun 202012:01 pmRNSForm 8.3 - Midatech Pharma PLC
18th Jun 20206:25 pmRNSForm 8 (DD) - Midatech Pharma plc
17th Jun 20207:00 amRNSGrant of Options
16th Jun 202010:20 amRNSInvestor Presentation
16th Jun 20207:00 amRNSResults for the year ended 31 December 2019
11th Jun 20203:41 pmRNSForm 8.3 - Midatech Pharma PLC
11th Jun 20203:35 pmRNSForm 8.3 - Midatech Pharma Plc
11th Jun 202010:53 amEQSForm 8.3 - Link Fund Solutions Ltd: Midatech Pharma Plc (Replacement)
11th Jun 20207:00 amRNSHolding(s) in Company
11th Jun 20207:00 amRNSHolding(s) in Company
10th Jun 20202:00 pmRNSPrice Monitoring Extension
10th Jun 202012:57 pmRNSForm 8.3 - Midatech Pharma plc
10th Jun 202011:00 amRNSPrice Monitoring Extension
9th Jun 20205:35 pmRNSForm 8.3 - Midatech Pharma plc
9th Jun 20204:36 pmRNSPrice Monitoring Extension
9th Jun 20204:04 pmRNSPurported Termination of MTX110 Licence Agreement
9th Jun 20202:48 pmEQSForm 8.3 - Link Fund Solutions Ltd: Midatech Pharma PLC
9th Jun 202012:14 pmRNSForm 8.3 - Midatech Pharma plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.